The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

@article{Gladding2008ThePA,
  title={The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.},
  author={Patrick A Gladding and Mark Wi Webster and Irene Sl Zeng and Helen B Farrell and Jim Stewart and Peter R. Ruygrok and John A Ormiston and Seif S El-Jack and Guy P. Armstrong and Patrick Kay and Douglas A. Scott and Arzu Gunes and M. -L. Dahl},
  journal={JACC. Cardiovascular interventions},
  year={2008},
  volume={1 6},
  pages={620-7}
}
OBJECTIVES This study assessed the effect of pharmacogenetics on the antiplatelet effect of clopidogrel. BACKGROUND Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 [CYP] family), transport proteins (P-glycoprotein) and/or target proteins for the drug (adenosine diphosphate-receptor P2Y12). METHODS Sixty patients undergoing elective percutaneous coronary intervention in the randomized PRINC (Plavix Response… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…